antileukemic

antileukemic

(ˌæntɪluːˈkiːmɪk)
adj
acting against leukemia
References in periodicals archive ?
A first Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi.
Phenethyl isothiocyanate exhibits antileukemic activity in vitro and in vivo by inactivation of Akt and activation of JNK pathways.
Following a clinical and regulatory strategy defining Type C dialogue with the FDA, the company plans to proceed with a clinical study design and biostatistical plan to support a Phase 3 registrational study for maintenance therapy for AML patients who have achieved complete remission after second line antileukemic therapy, or CR2.
Acute myeloid leukemia (AML) is a hematopoietic neoplasm of the myeloid line of blood cells.[1] Clinically, secondary heart tumors usually remain silent.[2] Several mechanisms have been suggested for the occurrence of cardiovascular disease during acute leukemia: leukemic thrombi or leukostasis in major arteries, leukemic infiltration into the myocardium or pericardium, and disorders of coagulation secondary to leukemia and antileukemic therapies.[3] We present a case of intracavitary heart masses in three heart chambers by AML.
Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia.
Derivatives of anthracene-9, 10-dione have attracted the attention of medicinal chemists due to a wide spectrum of significant pharmacological activities such as anti-tumour (Ashnagar et al., 2010; Ge and Russell, 1997), anti-inflammatory (Yadav et al., 2010), antimalarial (Osman et al., 2010; Yadav et al., 2010), antioxidants, antimicrobial (Yadav et al., 2010; Xiang et al., 2008), antifungal (Rath et al., 1995), antileukemic (Chang and Lee, 1984), antiviral and anti-HIV properties (Alves et al., 2004; Schinazi et al., 1990).
Antileukemic mechanisms induced by BET inhibitors, such as JQ1, are currently not well understood but are believed to involve suppression of MYC.
Our findings indicate a high percentage of central adiposity among subjects treated for childhood cancer, especially after antileukemic therapy, although the percentage of obese/overweight survivors was not high.
Castillo-Caro et al., "Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity," Clinical Cancer Research, vol.
Luetkens et al., "5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity," Mediators of Inflammation, vol.